ArticleHereditas2025
DExD-box helicase 39 A, targeted by coumestrol, facilitates the malignant behaviors of osteosarcoma cells.
Article in Hereditas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOsteosarcoma (OS) has a high degree of malignancy, is prone to metastasize. This study aims to identify new biomarkers and natural drugs for OS.
methodsOpen access OS-related datasets in Gene Expression Omnibus database (GSE39262, GSE21257 and GSE16088) were retrieved and analyzed. The genes related to OS progression were screened through differentially expressed gene analysis, weighted gene co-expression network analysis and univariate COX regression analysis. Immune infiltration analysis was performed using the CIBERSORT and ESTIMATE methods. The binding relationship between DExD-box helicase 39 A (DDX39A) and the natural drug coumerstrol was verified with molecular docking and cellular thermal shift assay. OS cell lines with DDX39A knockdown and overexpression were constructed respectively, to investigate the functions of DDX39A and coumerstrol. Cell viability, proliferation, apoptosis, cell cycle distribution, migration and invasion abilities were analyzed by CCK-8, EdU, flow cytometry and Transwell assays, respectively.
resultsDDX39A was highly expressed in OS samples and cell lines, associated with the poor prognosis of the patients. In vitro experiments confirmed that knockdown of DDX39A could inhibit the viability, proliferation, migration and invasion ability of OS cells, causing G1/S phase arrest and apoptosis. DDX39A had a good binding ability with coumerstrol. Coumerstrol treatment could inhibit the expression of DDX39A in OS cells and repressed the malignant behaviors of OS cells, while the overexpression of DDX39A reversed this phenomenon.
conclusionDDX39A is a promising biomarker and therapy target for OS, and coumestrol exerts tumor suppressive properties in OS via inhibiting DDX39A.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.